Document is current
Any future updates will be listed below
-
Authors
van der Pol, Ymke
Moldovan, Norbert
Ramaker, Jip
Bootsma, Sanne
Lenos, Kristiaan J.
Vermeulen, Louis
Sandhu, Shahneen
Bahce, Idris
Pegtel, D. Michiel
Wong, Stephen Q.
Dawson, Sarah-Jane https://orcid.org/0000-0002-8276-0374
Chandrananda, Dineika https://orcid.org/0000-0002-8834-9500
Mouliere, Florent https://orcid.org/0000-0001-7043-0514
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (KWF-12822)
National Health and Medical Research Council (#1196755, #1194783)
Victorian Cancer Agency
- License Information
-
More Information
Article History
Received: 22 August 2022
Accepted: 26 September 2023
First Online: 12 October 2023
Declarations
:
: All lung cancer patients and healthy individuals in cohort N were recruited following informed consent via the Liquid Biopsy Center at the Amsterdam UMC (locations: VUmc and AMC) as approved by the Amsterdam UMC ethics board (METC U2019_035). The breast cancer and melanoma patients as well as all healthy controls in cohort A were recruited following informed consent with each study approved by the Peter MacCallum Cancer Centre Human Research Ethics Committee (Breast HREC 15/72; Melanoma HREC 11/105 and 07/38; Healthy controls HREC 98/36 and 17/56).
: FM, DC and SJD are co-inventors on multiple patents related to cfDNA analysis. SJD has been an advisory board member for AstraZeneca, Inivata and Adela. Other co-authors have no relevant conflicts of interest.
